It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website ...

After years of ongoing shortages due to their growing popularity, all doses of both Ozempic and Wegovy are now listed as ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

In humans, nasal foralumab modulates immune responses by inducing regulatory-type T cells. Semaglutide is an effective ...

As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.74%) and Novo Nordisk (NVO -0.28%), there's now one more big reason to ex ...

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Tiziana Life Sciences (TLSA) announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody in combination ...